Product details
Background：IL-31 is a cytokine that is initially produced by activated T cells, especially Th2 cells, and is closely related to pathological processes such as inflammatory skin diseases and pruritus. The IL-31 receptor complex consists of two major components: the cell-surface receptor IL-31RA (aka IL-31 receptor a) and the signaling transmembrane protein Oncostatin m receptor-like subunit (OSMR, also known as part of the LGR1/βc receptor) . After the formation of functional complexes, they can trigger inflammatory response and neuro-immune coupling by downstream signaling pathways (such as Jak/Stat, MAPK, PI3K-AKT, etc.) , and promote itch transmission and inflammatory response. The IL-31/IL-31RA pathway is widely recognized to play a central role in pruritus and inflammation in multiple skin diseases, especially in eczema (atopic dermatitis, AD) and certain chronic inflammatory skin diseases. Nemolizuma is a monoclonal antibody that targets IL-31RA. By blocking the binding of Il-31 to IL-31RA, downstream signaling pathways are inhibited, thereby alleviating itching and inflammatory responses.
